News | July 20, 2012

Plavix, Clopidogrel and Atorvastatin Cardiac Drugs Among Leaders in U.S. Drug Sales

Drugs.com stats center lists the Top 100 U.S. Drugs for Q1 2012

July 20, 2012 — The online clinical drug resource Drugs.com released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood thinners, proton-pump inhibitors, antipsychotics and asthma therapeutic categories continue to remain top sellers.

Bristol-Myers Squibb's Plavix led the way with more than $1.6 billion in sales in the first quarter of 2012. However, the recent launch of clopidogrel (the generic version of Plavix) may alter these figures in upcoming quarters. Proton-pump inhibitor Nexium saw a small decline, while sales for Abilify and Singulair both exceeded $1 billion. The generic version of Singulair (montelukast) is slated for market entry in the third quarter of 2012.

"The most recent sales data from the first quarter of 2012 highlights the continued stronghold of several branded medications," said Philip Thornton, CEO of Drugs.com. "However, with generic versions of Plavix and Lipitor now available and with a number of established brands moving to first-time generic status in the coming years, lower-cost medications will enable patients to have greater access to lifesaving treatments and save billions in healthcare dollars."

Atorvastatin and its branded version Lipitor claim both the top gain and loss, respectively, in the first quarter. Atorvastatin made the biggest gain, bringing total sales in Q1 2012 to $952 million. As a comparison, Lipitor sales reached $1.9 billion in each of the first three quarters of 2011. Synagis, MedImmune's monoclonal antibody used for prevention of respiratory syncytial virus (RSV) in infants and young children, gained 38 percent.

Pfizer's cholesterol-lowering statin Lipitor lost patent protection in 2011 and sales of the brand dropped to 14th position. Eli Lilly's Zyprexa drops 43 places to 84th and closes the quarter with $194 million. Sales of Forest Laboratories' antidepressant Lexapro also declined due to the availability of its generic counterpart, escitalopram.

For more information: www.drugs.com/stats/top100/sales

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init